中国·金沙9570(官方)登录入口

Be the most trusted biotech company

2022-06-21

Henlius’ Songjiang First Plant Received QP Declaration of Its GMP Equivalence to EU GMP
2022-06-20

Henlius Attends BIO 2022
2022-06-17

First Subject Dosed in Phase 3 MRCT of Denosumab Biosimilar HLX14
2022-06-13

Henlius and Organon Enter into a License and Supply Agreement for Henlius’ Two Biologics in ex-China Countries
2022-06-07

First Subject Dosed of the Phase 1 Clinical Trial on Henlius Novel Anti-EGFR×4-1BB Bispecific Antibody HLX35 for the Treatment of Advanced or Metastatic Solid Tumours
2022-06-06

The Pivotal Trial Results for the Treatment of MSI-H/dMMR Solid Tumors of Anti-PD-1 mAb Serplulimab Released at 2022 ASCO Annual Meeting
2022-06-06

ASTRUM-005 | Henlius Released Phase 3 Study Results for the First-line Treatment of Small Cell Lung Cancer of Serplulimab at ASCO 2022
2022-05-24

Henlius and Abbott Entered into a Semi-Exclusive License Agreement of HANLIKANG and HANQUYOU in Brazil
2022-05-19

First Patient Dosed for MRCT Phase 3 Studies on First-Line LS-SCLC of Henlius Anti-PD-1 mAb Serplulimab